Cargando…

Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis

INTRODUCTION: Individualisation of rheumatoid arthritis (RA) treatment needs to take account of individual patients’ preferences to increase patient-centeredness in treatment decisions. The aim of this study was to identify patient-relevant treatment attributes to consider when individualising treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bywall, Karin Schölin, Esbensen, Bente Appel, Lason, Marta, Heidenvall, Marie, Erlandsson, Inger, Johansson, Jennifer Viberg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873051/
https://www.ncbi.nlm.nih.gov/pubmed/34655004
http://dx.doi.org/10.1007/s10067-021-05961-8
_version_ 1784657379159179264
author Bywall, Karin Schölin
Esbensen, Bente Appel
Lason, Marta
Heidenvall, Marie
Erlandsson, Inger
Johansson, Jennifer Viberg
author_facet Bywall, Karin Schölin
Esbensen, Bente Appel
Lason, Marta
Heidenvall, Marie
Erlandsson, Inger
Johansson, Jennifer Viberg
author_sort Bywall, Karin Schölin
collection PubMed
description INTRODUCTION: Individualisation of rheumatoid arthritis (RA) treatment needs to take account of individual patients’ preferences to increase patient-centeredness in treatment decisions. The aim of this study was to identify patient-relevant treatment attributes to consider when individualising treatment for patients with RA. METHOD: Patients with RA in Sweden were invited to rank the most important treatment attributes in an online survey (April to May 2020). Semi-structured interviews were conducted (October to November 2020) to further identify and frame potential attributes for shared decision-making. The interviews were audio-recorded, transcribed and analysed using thematic framework analysis. Patient research partners and rheumatologists supported the selection and framing of the treatment attributes across the assessment. RESULTS: The highest ranked attributes (N = 184) were improved functional capacity, reduced inflammation, reduced pain and fatigue and the risk of getting a severe side effect. The framework analysis revealed two overarching themes for further exploration: treatment goals and side effects. ‘Treatment goals’ emerged from functional capacity, revealing two dimensions: physical functional capacity and psychosocial functional capacity. ‘Side effects’ revealed that mild and severe side effects were the most important to discuss in shared decision-making. CONCLUSIONS: Functional capacity (physical and psychosocial) and potential side effects (mild and severe) are important treatment attributes to consider when individualising RA treatment. Future research should assess how patients with RA weigh benefits and risks against each other, in order to increase patient-centeredness early on the treatment trajectory.
format Online
Article
Text
id pubmed-8873051
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88730512022-03-02 Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis Bywall, Karin Schölin Esbensen, Bente Appel Lason, Marta Heidenvall, Marie Erlandsson, Inger Johansson, Jennifer Viberg Clin Rheumatol Original Article INTRODUCTION: Individualisation of rheumatoid arthritis (RA) treatment needs to take account of individual patients’ preferences to increase patient-centeredness in treatment decisions. The aim of this study was to identify patient-relevant treatment attributes to consider when individualising treatment for patients with RA. METHOD: Patients with RA in Sweden were invited to rank the most important treatment attributes in an online survey (April to May 2020). Semi-structured interviews were conducted (October to November 2020) to further identify and frame potential attributes for shared decision-making. The interviews were audio-recorded, transcribed and analysed using thematic framework analysis. Patient research partners and rheumatologists supported the selection and framing of the treatment attributes across the assessment. RESULTS: The highest ranked attributes (N = 184) were improved functional capacity, reduced inflammation, reduced pain and fatigue and the risk of getting a severe side effect. The framework analysis revealed two overarching themes for further exploration: treatment goals and side effects. ‘Treatment goals’ emerged from functional capacity, revealing two dimensions: physical functional capacity and psychosocial functional capacity. ‘Side effects’ revealed that mild and severe side effects were the most important to discuss in shared decision-making. CONCLUSIONS: Functional capacity (physical and psychosocial) and potential side effects (mild and severe) are important treatment attributes to consider when individualising RA treatment. Future research should assess how patients with RA weigh benefits and risks against each other, in order to increase patient-centeredness early on the treatment trajectory. Springer International Publishing 2021-10-15 2022 /pmc/articles/PMC8873051/ /pubmed/34655004 http://dx.doi.org/10.1007/s10067-021-05961-8 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Bywall, Karin Schölin
Esbensen, Bente Appel
Lason, Marta
Heidenvall, Marie
Erlandsson, Inger
Johansson, Jennifer Viberg
Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis
title Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis
title_full Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis
title_fullStr Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis
title_full_unstemmed Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis
title_short Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis
title_sort functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873051/
https://www.ncbi.nlm.nih.gov/pubmed/34655004
http://dx.doi.org/10.1007/s10067-021-05961-8
work_keys_str_mv AT bywallkarinscholin functionalcapacityvssideeffectstreatmentattributestoconsiderwhenindividualisingtreatmentforpatientswithrheumatoidarthritis
AT esbensenbenteappel functionalcapacityvssideeffectstreatmentattributestoconsiderwhenindividualisingtreatmentforpatientswithrheumatoidarthritis
AT lasonmarta functionalcapacityvssideeffectstreatmentattributestoconsiderwhenindividualisingtreatmentforpatientswithrheumatoidarthritis
AT heidenvallmarie functionalcapacityvssideeffectstreatmentattributestoconsiderwhenindividualisingtreatmentforpatientswithrheumatoidarthritis
AT erlandssoninger functionalcapacityvssideeffectstreatmentattributestoconsiderwhenindividualisingtreatmentforpatientswithrheumatoidarthritis
AT johanssonjenniferviberg functionalcapacityvssideeffectstreatmentattributestoconsiderwhenindividualisingtreatmentforpatientswithrheumatoidarthritis